All News
FOREMOST: Apremilast in Early Oligoarticular Psoriatic Arthritis
A controlled trial has shown that apremilast is effective in patients with early, oligoarticular psoriatic arthritis (PsA).
Increased Cardiovascular Events in Lupus
A New York surveillance registry (Manhattan Lupus Surveillance Program) estimates higher rates of cardiovascular events (CVE) among systemic lupus erythematosus (SLE) patients, especially amongst younger males, Hispanic/Latinos and non-Hispanic Black patients.
Read Article
BSR Guidelines for Systemic Sclerosis Management
The British Society for Rheumatology (BSR) has updated its 2015 guidelines for the management of patients with sytemic sclerosis (SSc) based on published evidence, systematic literature review and expert opinion.
Read Article
Congrats to 2024 recipients of the Lupus Research Alliance Diversity in Lupus Research Awards:
- Carlos Castrillon PhD, Emory
- Paul Hoover MD, PhD, Brigham
- Renita Horton PhD, U Houston
- Rodrigo Cervantes-Díaz PhD, Boston Childrens
- Jonathan Lagos Orellana MD PhD, Seattle… https://t.co/gtvT4kt7Lt https://t.co/MOdxH2cPM1
Dr. John Cush RheumNow ( View Tweet)
2612 BSRBR-RA Registry pts on tocilizumab - increasing Body weight was associated with reduced DAS28 response to SC tocilizumab. But the DAS28 difference was small, and did not change drug persistence https://t.co/eR7kmjRaEE https://t.co/vFKYC1I3pV
Dr. John Cush RheumNow ( View Tweet)
Chinese study of 62 Systemic JIA pts Rx w/ IV Tocilizumab (34 12 mg/kg; 28 8 mg/kg). Wk12 87% responded (JIA ACR 30w/ no fever); Week 52 results were similar. No deaths or macrophage activation syndrome occurred. https://t.co/qGgMCt597x https://t.co/lFDxAgDHfW
Dr. John Cush RheumNow ( View Tweet)
Swedish population/registry study of incidence of Psoriatic arthritis was estimated at 21.8/100 000 person-years (15.78-28.83/100 000 PY); slightly higher in females, lower w/ higher education, peaks 50-59y. 71% were on DMARD w/in 2 yrs (22% b/ts DMARDs) https://t.co/YTNBHczZ7X https://t.co/KNscF08fKG
Dr. John Cush RheumNow ( View Tweet)
Retrospective Taiwan's Health claims: studied 6408 RA pts, half HCQ users vs non-users. No higher risk of osteoporosis in HCQ users vs non-users (aHR=0.99; 95% CI: 0.82–1.196). Why study this? HCQ may suppress both bone formation/resorption https://t.co/xShLXMElnH https://t.co/lkvihaYuAd
Dr. John Cush RheumNow ( View Tweet)
Different Autoantibody Phenotypes in Juvenile and Adult Myositis
A Kyoto University study compared juvenile-idiopathic inflammatory myopathy (IIM) and adult-IIM patients, demonstrating different autoantibody profiles and a more favorable outcome for n juvenile-IIM patients.… https://t.co/fHL14rXAQ6 https://t.co/ZagRU62joJ
Dr. John Cush RheumNow ( View Tweet)
Systemic Sclerosis Insights (9.13.2024)
https://t.co/fRbKdSAqxG https://t.co/PMbYDXPHMd
Dr. John Cush RheumNow ( View Tweet)
Congratulations to UCF Associate Professor Justine Tigno-Aranjuez for receiving prestigious U.S. National Science Foundation CAREER Award on her research into NOD2 receptor signaling of lipid mediators contributing to inflammation https://t.co/AkUZbdTSqF https://t.co/usTe2bzyXE
Dr. John Cush RheumNow ( View Tweet)
24 wk RCT of 683 chronic neck pain pts -acupuncture was more effective in reducing neck pain than sham or waiting (observation), but the magnitude of benefit was below the minimal clinically important change. https://t.co/sqNV8XFYRl https://t.co/hI5Y3z6JiK
Dr. John Cush RheumNow ( View Tweet)
“Big doors swing on little hinges.”
- W. Clement Stone https://t.co/wLfKpwUxzc
Dr. John Cush RheumNow ( View Tweet)
1,717 Chinese rheumatologists (92% response) surveyed on Steroid use in RA. 60% admit to infrequent use of GC cotherapy. Bridging GC use was supported (35%), opposed (27%), but 38% were inconclusive & 67% said long-term low-dose GC use depends on the pt https://t.co/7qe1aRsZx8 https://t.co/D0RoYxPohY
Dr. John Cush RheumNow ( View Tweet)
Animal model shows Aggregatibacter actinomycetemcomitans periodontitis can trigger macrophage/caspase-11/inflammasome activation leading to paw swelling in mice anti-collagen antibody-induced arthritis (CAIA) model https://t.co/f41r28g5yr https://t.co/61NeXgfzmB
Dr. John Cush RheumNow ( View Tweet)
Norwegian Registry study compared risk of stroke in 2750 RA vs 158 879 w/o RA pts. 7.3 vs 5% (HR 1.36; 1.13, 1.62). RA pts with atrial fibrillation was also elevated (HR 1.25; 1.05, 1.5). RA pts less likely to Rx w/ oral anticoagulants (adj OR 0.88) than non-RA… https://t.co/uprHZbsqkR https://t.co/edjoN2vzc0
Dr. John Cush RheumNow ( View Tweet)
REAL-HLH, a retrospective study of emapalumab (anti-IFNg) was effective in Rheum (15 pts) w/ hemophagocytic lymphohistiocytosis (10 w/ Still's disease, 60% in ICU w/ refractory Dz). EMA normalized CXCL9, ANC, decr steroids & had 12 mo survival=87% https://t.co/MgYul9rCqV https://t.co/pDpriVvAdg
Dr. John Cush RheumNow ( View Tweet)
CAR-T Like Effects with Bispecific Teclistamab
A new chapter may have begun in the exciting story of "immune reset" therapy for difficult-to-treat autoimmune diseases, with a patient with severe refractory lupus obtaining drug-free remission after treatment with an antibody… https://t.co/FO42QaJaFn https://t.co/5LouAzYeOv
Dr. John Cush RheumNow ( View Tweet)
Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/yIBlyNZacB https://t.co/dempwjX5XO
Dr. John Cush RheumNow ( View Tweet)
Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb
Dr. John Cush RheumNow ( View Tweet)